Blødning er den mest almindeligt indrapporterede bivirkning fra både kliniske studier, såvel som fra post- marketing erfaring, hvor den mestendels blev indrapporteret i løbet behandlingens første måned.
Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience where it was mostly reported during the first month of treatment.